Landscape Capital Management L.L.C. Makes New Investment in IO Biotech, Inc. (NASDAQ:IOBT)

Landscape Capital Management L.L.C. acquired a new stake in IO Biotech, Inc. (NASDAQ:IOBT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 442,196 shares of the company’s stock, valued at approximately $407,000.

Separately, Vontobel Holding Ltd. acquired a new stake in IO Biotech in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 54.76% of the company’s stock.

IO Biotech Stock Down 7.5 %

Shares of NASDAQ:IOBT opened at $0.91 on Tuesday. The business’s 50 day moving average is $0.97 and its 200 day moving average is $0.97. IO Biotech, Inc. has a 12-month low of $0.66 and a 12-month high of $1.79. The stock has a market cap of $59.95 million, a price-to-earnings ratio of -0.66 and a beta of 0.08.

Analyst Upgrades and Downgrades

IOBT has been the topic of several research reports. Piper Sandler upgraded shares of IO Biotech to a “strong-buy” rating in a report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of IO Biotech in a report on Tuesday, April 1st.

IO Biotech Company Profile

IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.